drugset / Trial / NCT02442557
Safety and Dose-finding Study of DC-TAB in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine safety and appropriate dose of DC-TAB for selective immune tolerance induction in humans.
Timeline
- Start
- 2009-12
- Primary completion
- 2010-10
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | recombinant human alpha B-crystallin | Protein / enzyme biologic | 4 mg | Intravenous |
| Comparator | recombinant human alpha B-crystallin | Protein / enzyme biologic | 10 mg | Intravenous |
| Comparator | recombinant human alpha B-crystallin | Protein / enzyme biologic | 12.5 mg | Intravenous |
| Comparator | recombinant human alpha B-crystallin | Protein / enzyme biologic | 25 mg | Intravenous |
| Comparator | recombinant human alpha B-crystallin | Protein / enzyme biologic | 37.5 mg | Intravenous |